REGENERON PHARMACEUTICALS,INC. (NASDAQ:REGN) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On January 9, 2017, at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, California (the “2017 J.P. Morgan Healthcare Conference”), Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), is providing a corporate update. Dr. Schleifer’s presentation includes information regarding the Company’s preliminary (unaudited) U.S. net sales of EYLEA® (aflibercept) Injection of $858 million and $3.32 billion for the fourth quarter 2016 and the full year 2016, respectively, and the preliminary (unaudited) global sales of EYLEA of more than $5 billion for the full year 2016.
Item 7.01. Regulation FD Disclosure.
The information set forth under Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 to this Current Report on Form 8-K is incorporated by reference herein.
On January 11, 2017, at a sell-side investor meeting at the 2017 J.P. Morgan Healthcare Conference, Robert E. Landry, Senior Vice President, Finance and Chief Financial Officer of Regeneron, is giving a presentation entitled “2017 Financial Overview.” A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
The information included or incorporated in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
99.1 Presentation by Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., at the 35th Annual J.P. Morgan Healthcare Conference.
99.2 Presentation by Robert E. Landry, Senior Vice President, Finance and Chief Financial Officer of Regeneron Pharmaceuticals, Inc., entitled “2017 Financial Overview.”
